View in EDS PDF Full Text

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.

Saved in:
Bibliographic Details
Title: High CYP2C19 phenotypic variability in gastrointestinal cancer patients.
Authors: Burns KE; Department of Molecular Medicine and Pathology, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. k.burns@auckland.ac.nz., Lo WY; Department of Molecular Medicine and Pathology, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand., Findlay MP; Discipline of Oncology, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.; Cancer Trials New Zealand, University of Auckland, Auckland, New Zealand., Sharples K; Cancer Trials New Zealand, University of Auckland, Auckland, New Zealand.; Department of Preventive and Social Medicine, University of Otago, PO Box 56, Dunedin, 9054, New Zealand., Laking G; Auckland City Hospital, Private Bag 92024, Auckland, 1142, New Zealand., Helsby NA; Department of Molecular Medicine and Pathology, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Jan; Vol. 77 (1), pp. 195-204. Date of Electronic Publication: 2015 Nov 27.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0843
DOI:10.1007/s00280-015-2923-4